...
首页> 外文期刊>Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry >X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins
【24h】

X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins

机译:X射线吸收光谱法研究细胞毒性金化合物与两种主要血清蛋白之间形成的加合物

获取原文
获取原文并翻译 | 示例

摘要

Gold metallodrugs form a class of promising antiproliferative agents showing a high propensity to react with proteins. We exploit here X-ray absorption spectroscopy (XAS) methods [both X-ray absorption near-edge spectroscopy (XANES) and extended X-ray absorption fine structure (EXAFS)] to gain insight into the nature of the adducts formed between three representative gold(I, III) metallodrugs (i.e., auranofin, [Au(2,2′-bipyridine)(OH) 2] (PF6), Aubipy, and dinuclear [Au2(6, 6′-dimethyl-2,2′- bipyridine)2(μ-O)2](PF 6)2, Auoxo6) and two major plasma proteins, namely, bovine serum albumin (BSA) and human serum apotransferrin (apoTf). The following metallodrug- protein systems were investigated in depth: auranofin/ apoTf, Aubipy/BSA, and Auoxo6/apoTf. XANES spectra revealed that auranofin, upon protein binding, conserves its gold(I) oxidation state. Protein binding most probably takes place through release of the thiosugar ligand and its subsequent replacement by a thiol (or a thioether) from the protein. This hypothesis is independently supported by EXAFS results. In contrast, the reactions of Aubipy with serum albumin and of Auoxo6 with serum apoTf invariantly result in gold(III) to gold(I) reduction. Gold(III) reduction, clearly documented by XANES, is accompanied, in both cases, by release of the bipyridyl ligands; for Auoxo6 cleavage of the gold-gold dioxo bridge is also observed. Gold(III) reduction leads to formation of proteinbound gold(I) species, with deeply modified metal coordination environments, as evidenced by EXAFS. In these adducts, the gold(I) centers are probably anchored to the protein through nitrogen donors. In general, these two XAS methods, i.e., XANES and EXAFS, used here jointly, allowed us to gain independent structural information on metallodrug/protein systems; detailed insight into the gold oxidation state and the local environment of protein-bound metal atoms was achieved in the various cases.
机译:金金属药物形成一类有前途的抗增殖剂,显示出与蛋白质反应的高度倾向。我们在这里利用X射线吸收光谱(XAS)方法[X射线吸收近边缘光谱(XANES)和扩展的X射线吸收精细结构(EXAFS)]来深入了解三个代表性化合物之间形成的加合物的性质金(I,III)金属药物(即金诺芬,[Au(2,2'-联吡啶)(OH)2](PF6),Aubipy和双核[Au2(6,6'-二甲基-2,2'- Bipyridine)2(μ-O)2](PF 6)2,Auoxo6)和两种主要血浆蛋白,即牛血清白蛋白(BSA)和人血清载铁蛋白(apoTf)。深入研究了以下金属药物-蛋白质系统:金诺芬/ apoTf,Aubipy / BSA和Auoxo6 / apoTf。 XANES光谱显示金诺芬经过蛋白质结合后可保留其金(I)氧化态。蛋白质结合最有可能通过释放硫糖配体并随后被蛋白质中的硫醇(或硫醚)取代而发生。 EXAFS结果独立支持此假设。相反,Aubipy与血清白蛋白的反应和Auoxo6与血清apoTf的反应始终导致金(III)还原为金(I)。 XANES明确记录的金(III)还原在两种情况下都伴随有联吡啶配体的释放;对于Auoxo6,还观察到金-金二氧代桥的裂解。金(III)的还原导致形成蛋白质结合的金(I)物种,并具有深度修饰的金属配位环境,如EXAFS所证明。在这些加合物中,金(I)中心可能通过氮供体锚定在蛋白质上。总的来说,这两种XAS方法,即XANES和EXAFS,在这里共同使用,使我们能够获得有关金属药物/蛋白质系统的独立结构信息;在各种情况下,都可以深入了解金的氧化态和蛋白质结合的金属原子的局部环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号